Sex hormone binding globulin, cortisol binding globulin, thyroxine binding globulin, ceruloplasmin: changes in treatment with two oral contraceptives low in oestrogen

It is generally assumed that the oral contraceptives cause the carrier proteins to change. Notoriously this effect is used to evaluate indirectly their estrogenicity/gestagenicity ratio. In order to assess the residual intrinsic androgenic activity of two new 19-nor-derivative components, Desogestre...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental obstetrics & gynecology Vol. 18; no. 1; p. 43
Main Authors Sobbrio, G A, Granata, A, Granese, D, D'Arrigo, F, Panacea, A, Nicita, R, Pullè, C, Trimarchi, F
Format Journal Article
LanguageEnglish
Published Canada 1991
Subjects
Carrier Proteins - metabolism
Ceruloplasmin - metabolism
Contraceptives, Oral, Combined - pharmacology
Desogestrel
Ethinyl Estradiol - pharmacology
Female
Humans
Norpregnenes - pharmacology
Serum Globulins - metabolism
Sex Hormone-Binding Globulin - metabolism
Testosterone - blood
Thyroxine-Binding Proteins - metabolism
Hemic System
Contraceptive Agents > pharmacodynamics
Adrenal Cortex Hormones
Biology
Hormones
Research Methodology
Oral Contraceptives, Combined
Clinical Research
Contraceptive Agents, Estrogen > pharmacodynamics
Contraceptive Methods
Physiology
Oral Contraceptives
Serum Protein Effects
Contraceptive Agents, Female > pharmacodynamics
Contraception
Family Planning
Desogestrel > pharmacodynamics
Endocrine System
Androgens
Contraceptive Agents, Progestin > pharmacodynamics
Gestodene > pharmacodynamics
Treatment
Blood Proteins
Hematological Effects
Ethinyl Estradiol > pharmacodynamics
Online AccessGet more information

Cover

More Information
Summary:It is generally assumed that the oral contraceptives cause the carrier proteins to change. Notoriously this effect is used to evaluate indirectly their estrogenicity/gestagenicity ratio. In order to assess the residual intrinsic androgenic activity of two new 19-nor-derivative components, Desogestrel (DG) 150 micrograms and Gestodene (GD) 75 micrograms, both in association with Ethinylestradiol (EE) 30 micrograms, Sex Hormone Binding Globulin, Thyroxine Binding Globulin, Ceruloplasmin and Free Androgen Index (FAI), were studied in 40 young normally cycling healthy volunteers, matched for body mass index and age. The participants were randomly assigned to either EE-DG or EE-GD treatment. A marked significant increase in all the carrier proteins was found. Conversely, the values for FAI decreased significantly. The changes in the two groups were substantially of the same magnitude. These results are an indirect confirmation of the well-known negligible receptor binding affinity of the two progestogen in vitro, also supporting for these compounds the lack of relevant androgenic effects.
ISSN:0390-6663